Clinical Trial Update: Self-administration of Subcutaneous Elranatamab in the Patients' Homes. [Phase 2]

View source ↗

Summary

Phase 2 trial update on self-administration of subcutaneous elranatamab at patients' homes for multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Elranatamab (elranatamab)

Snippet

Sponsor: Thomas Lund | Conditions: Multiple Myeloma | Phase 2 | Status: RECRUITING